Evidence from cell, animal, and human studies demonstrates that α1-adrenergic receptors mediate adaptive and protective effects in the heart. These effects may be particularly important in chronic heart failure, when catecholamine levels are elevated and β-adrenergic receptors are down-regulated and dysfunctional. This review summarizes these data and proposes that selectively activating α1-adrenergic receptors in the heart might represent a novel and effective way to treat heart failure. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure".
Bibliographical noteFunding Information:
We thank the NIH (B.C.J., T.D.O., P.C.S.); the Department of Veterans Affairs Research Service (P.C.S.); the GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease (B.C.J.); the University of California, San Francisco, Foundation for Cardiac Research (B.C.J.); the American Heart Association, Western States Affiliate (P.C.S.); and the American Heart Association, Greater Midwest Affiliate (T.D.O.).
- Alpha-1-Adrenergic receptors
- Cardiac myocytes
- Drug development
- Heart failure